EYEVENSYS S.A.S.   Report issue

For profit Phase 2
Founded: Paris France (2008)

Organization Overview

First Clinical Trial
2017
NCT03308045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Eyevensys | EYEVENSYS S.A.S.

Active Ingredients

Drugs in Phase 2 Trials (1)

peys606 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Panuveitis (Phase 2)

Uveitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1